EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC
Clinical trial NCT03720873 · UNKNOWN
Trial details
- NCT number
- NCT03720873
- Sponsor
- Fujian Cancer Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-10-01
- Primary completion
- 2021-06-01
- Enrollment
- 90
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.